Physician profile
Fahed Hamadeh
NPI 1194760918
$7,602.64
in general payments reported to CMS, 2019-2025
12 companies · $2,808 in 2025
The $2,808 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $313 · 2021: $262 · 2022: $736 · 2023: $2,669 · 2024: $166 · 2025: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,900 · Food and Beverage: $1,261 · Travel and Lodging: $265 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,900.00 |
| Food and Beverage | $1,261.31 |
| Travel and Lodging | $264.62 |
| Education | $217.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,039.61 | 2019-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $666.50 | 2019-2025 | Benlysta |
| Abbvie INC. | $498.24 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $347.71 | 2019-2022 | |
| Allergan, INC. | $295.00 | 2022 | |
| Amgen INC. | $287.35 | 2022-2023 | Tavneos |
| Aurinia Pharma U.S., INC. | $199.60 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $118.92 | 2022-2023 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $108.15 | 2019 | |
| Celgene Corporation | $21.09 | 2019 | |
| Nalu Medical, INC. | $20.47 | 2024 | Nalu Neurostimulation System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahed Hamadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.